219 related articles for article (PubMed ID: 30793701)
1. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.
Arnaud L; Mertz P; Gavand PE; Martin T; Chasset F; Tebacher-Alt M; Lambert A; Muller C; Sibilia J; Lebrun-Vignes B; Salem JE
Ann Rheum Dis; 2019 Apr; 78(4):504-508. PubMed ID: 30793701
[TBL] [Abstract][Full Text] [Related]
2. Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase.
Vollmer O; Felten R; Mertz P; Lebrun-Vignes B; Salem JE; Arnaud L
Autoimmun Rev; 2020 Mar; 19(3):102460. PubMed ID: 31917266
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced antiphospholipid syndrome: Analysis of the WHO international database.
Gérardin C; Bihan K; Salem JE; Khachatryan H; Gerotziafas G; Fain O; Mekinian A
Autoimmun Rev; 2022 May; 21(5):103060. PubMed ID: 35114404
[TBL] [Abstract][Full Text] [Related]
4. Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database.
Dumont A; Dolladille C; de Boysson H; Alexandre J; Nguyen A; Deshayes S; Aouba A
Autoimmun Rev; 2022 Sep; 21(9):103157. PubMed ID: 35902047
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
[TBL] [Abstract][Full Text] [Related]
6. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
Aghdashi MA; Khadir M; Dinparasti-Saleh R
Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
[TBL] [Abstract][Full Text] [Related]
7. Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.
Shovman O; Tamar S; Amital H; Watad A; Shoenfeld Y
Clin Rheumatol; 2018 Feb; 37(2):563-568. PubMed ID: 29063464
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
9. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
11. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL;
Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced systemic lupus erythematosus.
Stratton MA
Clin Pharm; 1985; 4(6):657-63. PubMed ID: 2866863
[TBL] [Abstract][Full Text] [Related]
13. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN
Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924
[TBL] [Abstract][Full Text] [Related]
14. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.
Hoisnard L; Lebrun-Vignes B; Maury S; Mahevas M; El Karoui K; Roy L; Zarour A; Michel M; Cohen JL; Amiot A; Claudepierre P; Wolkenstein P; Grimbert P; Sbidian E
Sci Rep; 2022 May; 12(1):7140. PubMed ID: 35504889
[TBL] [Abstract][Full Text] [Related]
15. [Pay close attention to drug-induced lupus].
Zhou MJ; Ni ZH
Zhong Xi Yi Jie He Xue Bao; 2008 May; 6(5):458-62. PubMed ID: 18471407
[TBL] [Abstract][Full Text] [Related]
16. A Worldwide Pharmacoepidemiologic Update on Drug-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Era of Targeted Therapies.
Deshayes S; Dolladille C; Dumont A; Martin Silva N; Chretien B; De Boysson H; Alexandre J; Aouba A
Arthritis Rheumatol; 2022 Jan; 74(1):134-139. PubMed ID: 34164938
[TBL] [Abstract][Full Text] [Related]
17. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study.
Pijnenburg L; Salem JE; Lebrun-Vignes B; Sibilia J; Javier RM; Arnaud L
Eur J Endocrinol; 2021 Mar; 184(3):437-444. PubMed ID: 33449911
[TBL] [Abstract][Full Text] [Related]
19. Epitope mapping of histone 5 (H5) with systemic lupus erythematosus, procainamide-induced lupus and hydralazine-induced lupus sera.
Pauls JD; Edworthy SM; Fritzler MJ
Mol Immunol; 1993 Jun; 30(8):709-19. PubMed ID: 7684819
[TBL] [Abstract][Full Text] [Related]
20. Antibodies from patients with systemic lupus erythematosus and drug-induced lupus bind determinants on histone 5 (H5).
Pauls JD; Gohill J; Fritzler MJ
Mol Immunol; 1990 Aug; 27(8):701-11. PubMed ID: 1698256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
